2',3'-(1-methylethylidene)-N⁶,N-diethyladenosine | 109680-71-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2',3'-(1-methylethylidene)-N⁶,N-diethyladenosine
• 英文别名: 2',3'-O-isopropylidene-N⁶-diethyladenosine；6-N,N-diethyl-2',3'-O-isopropylideneadenosine；((3aR,4R,6R,6aR)-6-(6-(diethylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol；[(3aR,4R,6R,6aR)-4-[6-(diethylamino)purin-9-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol
• CAS: 109680-71-9
• 化学式: C₁₇H₂₅N₅O₄
• 分子量: 363.417
• InChiKey: ABKYLEUUIMDCNB-XNIJJKJLSA-N

物化性质

• 沸点：
  554.0±60.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2',3'-(1-methylethylidene)-N⁶,N-diethyladenosine 在 磷酸三甲酯 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.25h， 生成 N⁶,N⁶-diethylpurine riboside-5'-O-[(phosphonomethyl)phosphonic acid]
  参考文献：
  名称：

  α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors

  摘要：

  ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics. The eN inhibitor alpha,beta-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared. Products were tested at rat recombinant eN. 6-(Ar)alkylamino substitution led to the largest improvement in potency. N-6-Monosubstitution was superior to symmetrical N-6,N-6-disubstitution. The most potent inhibitors were N-6-(4chlorobenzyl)-(10l, PSB-12441, K-i 7.23 n.M), N-6-phenylethyl(10h, PSB-12425, K-i 8.04 nM), and N-6-benzyl-adenosine-5'-O[(phosphonomethyl)phosphonic acid] (10g, PSB-12379, K-i 9.03 nM). Replacement of the 6-NH group in 10g by 0 (10q, PSB-12431) or S (10r, PSB-12553) yielded equally potent inhibitors (10q, 9.20 nM; 10r, 9.50 aM). Selected compounds investigated at the human enzyme did not show species differences; they displayed high selectivity versus other ecto-nudeotidases and ADP-activated P2Y receptors. Moreover, high metabolic stability was observed. These compounds represent the most potent eN inhibitors described to date.

  DOI：

  10.1021/acs.jmedchem.5b00802
• 作为产物：
  描述：

  2’,3’,5’-三乙酰肌苷 在 4-二甲氨基吡啶 、 硫酸 、 氨 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.34h， 生成 2',3'-(1-methylethylidene)-N⁶,N-diethyladenosine
  参考文献：
  名称：

  α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors

  摘要：

  ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics. The eN inhibitor alpha,beta-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared. Products were tested at rat recombinant eN. 6-(Ar)alkylamino substitution led to the largest improvement in potency. N-6-Monosubstitution was superior to symmetrical N-6,N-6-disubstitution. The most potent inhibitors were N-6-(4chlorobenzyl)-(10l, PSB-12441, K-i 7.23 n.M), N-6-phenylethyl(10h, PSB-12425, K-i 8.04 nM), and N-6-benzyl-adenosine-5'-O[(phosphonomethyl)phosphonic acid] (10g, PSB-12379, K-i 9.03 nM). Replacement of the 6-NH group in 10g by 0 (10q, PSB-12431) or S (10r, PSB-12553) yielded equally potent inhibitors (10q, 9.20 nM; 10r, 9.50 aM). Selected compounds investigated at the human enzyme did not show species differences; they displayed high selectivity versus other ecto-nudeotidases and ADP-activated P2Y receptors. Moreover, high metabolic stability was observed. These compounds represent the most potent eN inhibitors described to date.

  DOI：

  10.1021/acs.jmedchem.5b00802

文献信息

• Reactions of trimethylsilyl fluorosulfonyldifluoroacetate with purine and pyrimidine nucleosides
  作者：Magdalena Rapp、Xiaohong Cai、Wei Xu、William R. Dolbier、Stanislaw F. Wnuk

  DOI：10.1016/j.jfluchem.2008.12.004

  日期：2009.3

  4-hydroxyl group of the enolizable uracil ring. Reaction of the difluorocarbene with the adenosine substrates having the unprotected 6-amino group in the purine ring produced the 6-N-difluoromethyl derivative, while reaction with 6-N-benzoyl protected adenosine analogues gave the difluoromethyl ether product derived from the insertion of difluorocarbene into the enol form of the 6-benzamido group. Treatment

  由氟磺酰二氟乙酸三甲基甲硅烷基酯 (TFDA) 生成的二氟卡宾优先在尿嘧啶环的烯醇化酰胺部分和嘌呤环的 6-氨基与尿苷和腺苷底物反应。2',3'- Di - O -benzoyl-3'-deoxy-3'-methyleneuridine 与 TFDA 反应生成 4- O-二氟甲基产物，其衍生自二氟卡宾插入可烯醇化尿嘧啶环的 4-羟基。二氟卡宾与嘌呤环中具有未保护的 6-氨基的腺苷底物反应产生 6- N-二氟甲基衍生物，同时与 6 -N-苯甲酰基保护的腺苷类似物得到二氟甲基醚产物，其衍生自二氟卡宾插入6-苯甲酰胺基的烯醇形式。用TFDA处理 6- N-邻苯二甲酰基保护的腺苷类似物导致嘌呤的咪唑环出人意料地一锅法转化为相应的N-二氟甲基硫脲衍生物。用 TFDA 处理在糖环的 2'、3' 或 4' 碳上带有外亚甲基的适当保护的嘧啶和嘌呤核苷，得到相应的螺二氟环丙基类似物，但产率低。
• Studies on compounds related to antitumor agents. Syntheses of 8-substituted N6,N6-dimethyladenosine derivatives.
  作者：TETSUO KATO、EITARO ARAKAWA、SHUICHI OGAWA、YASUKO SUZUMURA、TAKETOSHI KATO

  DOI：10.1248/cpb.34.3635

  日期：——

  N6, N6-Dimethyl-8-methylsulfonyladenosine, obtained from N6, N6-dimethyl-8-methylthioadenosine by highly selective oxidation with KMnO4, was treated with cyanide ion to give 8-cyano-N6, N6-dimethyladenosine. The conversion of the cyano group to methyl imidate, methoxycarbonyl, carbamoyl, carbothioamide, and carboxylic acid moieties was achieved. These 8-substituted N6, N6-dimethyladenosines may possess resonances structures involving positions 6 and 8 in adenosine, as indicated by the spectroscopic data. They showed no antitumor activity.

  N6, N6-二甲基-8-甲磺酰基腺苷是通过 KMnO4 高选择性氧化从 N6, N6-二甲基-8-甲硫基腺苷中得到的，用氰离子处理得到 8-氰基-N6, N6-二甲基腺苷。氰基可转化为亚胺酸甲酯、甲氧基羰基、氨基甲酰基、硫代磷酸甲酰胺和羧酸分子。光谱数据表明，这些 8-取代的 N6、N6-二甲基腺苷可能具有涉及腺苷中第 6 和第 8 位的共振结构。它们没有显示出抗肿瘤活性。
• Kinetic Analysis of the Rebek Self-Replicating System:  Is There a Controversy?
  作者：David N. Reinhoudt、Dmitry M. Rudkevich、Feike de Jong

  DOI：10.1021/ja960324g

  日期：1996.1.1

  reaction of 1 and 2, catalyzed by complexation of both reactants to the resulting product 3 (Tjivikua, T.; et al. J. Am. Chem. Soc. 1990, 112, 1249-1250. Nowick, J. S.; et al. J. Am. Chem. Soc. 1991, 113, 8831-8839. Wintner, E. A.; et al. Acc. Chem. Res. 1994, 27, 198-203. Conn, M. M.; et al. J. Am. Chem. Soc. 1994, 116, 8823-8824), and related work of Menger et al. (Menger, F. M.; et al. J. Am. Chem. Soc

  1 和 2 的 Rebek 自复制反应，由两种反应物与所得产物 3 络合催化（Tjivikua, T.；等人 J. Am. Chem. Soc. 1990, 112, 1249-1250. Nowick, JS ; et al. J. Am. Chem. Soc. 1991, 113, 8831-8839. Wintner, EA; et al. Acc. Chem. Res. 1994, 27, 198-203. Conn, MM; et al. J. Am. Chem. Soc. 1994, 116, 8823-8824)，以及 Menger 等人的相关工作。(Menger, FM; et al. J. Am. Chem. Soc. 1994, 116, 3613-3614. Menger, FM; et al. J. Org. Chem. 1995, 60, 2870-2878) 已
• α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective <i>ecto</i>-5′-Nucleotidase (CD73) Inhibitors
  作者：Sanjay Bhattarai、Marianne Freundlieb、Jan Pippel、Anne Meyer、Aliaa Abdelrahman、Amelie Fiene、Sang-Yong Lee、Herbert Zimmermann、Gennady G. Yegutkin、Norbert Sträter、Ali El-Tayeb、Christa E. Müller

  DOI：10.1021/acs.jmedchem.5b00802

  日期：2015.8.13

  ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics. The eN inhibitor alpha,beta-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared. Products were tested at rat recombinant eN. 6-(Ar)alkylamino substitution led to the largest improvement in potency. N-6-Monosubstitution was superior to symmetrical N-6,N-6-disubstitution. The most potent inhibitors were N-6-(4chlorobenzyl)-(10l, PSB-12441, K-i 7.23 n.M), N-6-phenylethyl(10h, PSB-12425, K-i 8.04 nM), and N-6-benzyl-adenosine-5'-O[(phosphonomethyl)phosphonic acid] (10g, PSB-12379, K-i 9.03 nM). Replacement of the 6-NH group in 10g by 0 (10q, PSB-12431) or S (10r, PSB-12553) yielded equally potent inhibitors (10q, 9.20 nM; 10r, 9.50 aM). Selected compounds investigated at the human enzyme did not show species differences; they displayed high selectivity versus other ecto-nudeotidases and ADP-activated P2Y receptors. Moreover, high metabolic stability was observed. These compounds represent the most potent eN inhibitors described to date.